Cardiff Oncology (CRDF) Competitors $4.07 -0.09 (-2.16%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$4.06 -0.02 (-0.37%) As of 07/11/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDF vs. PHVS, NRIX, PRAX, AKBA, SYRE, MLYS, SION, AVXL, ORIC, and LENZShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Pharvaris (PHVS), Nurix Therapeutics (NRIX), Praxis Precision Medicines (PRAX), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Sionna Therapeutics (SION), Anavex Life Sciences (AVXL), Oric Pharmaceuticals (ORIC), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. Cardiff Oncology vs. Its Competitors Pharvaris Nurix Therapeutics Praxis Precision Medicines Akebia Therapeutics Spyre Therapeutics Mineralys Therapeutics Sionna Therapeutics Anavex Life Sciences Oric Pharmaceuticals LENZ Therapeutics Cardiff Oncology (NASDAQ:CRDF) and Pharvaris (NASDAQ:PHVS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership. Which has higher valuation & earnings, CRDF or PHVS? Cardiff Oncology has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiff Oncology$680K398.20-$45.43M-$0.92-4.42PharvarisN/AN/A-$145.24M-$3.01-8.35 Does the media prefer CRDF or PHVS? In the previous week, Pharvaris had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 7 mentions for Pharvaris and 5 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.78 beat Pharvaris' score of 0.65 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CRDF or PHVS? Cardiff Oncology has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.82, meaning that its stock price is 382% less volatile than the S&P 500. Do analysts recommend CRDF or PHVS? Cardiff Oncology presently has a consensus price target of $11.70, indicating a potential upside of 187.47%. Pharvaris has a consensus price target of $36.20, indicating a potential upside of 44.11%. Given Cardiff Oncology's higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than Pharvaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Pharvaris 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in CRDF or PHVS? 16.3% of Cardiff Oncology shares are owned by institutional investors. 7.7% of Cardiff Oncology shares are owned by insiders. Comparatively, 11.8% of Pharvaris shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is CRDF or PHVS more profitable? Pharvaris has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,308.50%. Pharvaris' return on equity of -54.02% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Cardiff Oncology-8,308.50% -76.45% -62.85% Pharvaris N/A -54.02%-50.36% SummaryCardiff Oncology beats Pharvaris on 8 of the 14 factors compared between the two stocks. Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDF vs. The Competition Export to ExcelMetricCardiff OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$276.75M$2.97B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-4.4220.7128.1020.27Price / Sales398.20292.05429.7098.72Price / CashN/A42.8637.4658.16Price / Book2.197.638.045.49Net Income-$45.43M-$55.05M$3.18B$250.45M7 Day Performance11.32%8.43%3.62%4.78%1 Month Performance7.39%5.42%4.05%7.67%1 Year Performance62.15%2.03%30.00%16.43% Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDFCardiff Oncology1.2844 of 5 stars$4.07-2.2%$11.70+187.5%+64.8%$276.75M$680K-4.4220Analyst ForecastPHVSPharvaris1.4363 of 5 stars$18.00-3.2%$36.20+101.1%+37.7%$972.60MN/A0.0030News CoverageNRIXNurix Therapeutics1.5971 of 5 stars$12.36-2.9%$30.18+144.1%-43.5%$970.48M$54.55M-4.41300Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap DownPRAXPraxis Precision Medicines2.4327 of 5 stars$46.68-1.2%$92.11+97.3%+1.1%$962.64M$8.55M0.00110Analyst ForecastAKBAAkebia Therapeutics3.5829 of 5 stars$3.63+0.3%$6.75+86.0%+209.4%$950.74M$160.18M-17.28430SYRESpyre Therapeutics1.9383 of 5 stars$15.30-2.9%$53.40+249.0%-44.2%$949.94M$890K-4.0673MLYSMineralys Therapeutics2.3579 of 5 stars$13.53-6.9%$32.25+138.4%+6.8%$947.65MN/A0.0028SIONSionna TherapeuticsN/A$20.96-1.1%$38.50+83.7%N/A$935MN/A0.0035News CoveragePositive NewsAVXLAnavex Life Sciences3.7909 of 5 stars$9.99-7.4%$44.00+340.4%+124.9%$921.16MN/A-18.1640News CoverageORICOric Pharmaceuticals4.656 of 5 stars$10.65-1.4%$19.17+80.0%+15.6%$920.42MN/A-5.7080Analyst ForecastLENZLENZ Therapeutics1.3661 of 5 stars$31.48-3.2%$46.60+48.0%+76.9%$915.59MN/A0.00110Analyst Revision Related Companies and Tools Related Companies PHVS Competitors NRIX Competitors PRAX Competitors AKBA Competitors SYRE Competitors MLYS Competitors SION Competitors AVXL Competitors ORIC Competitors LENZ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDF) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRDF Stock Alerts